Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 6
2000 3
2001 3
2004 1
2009 1
2010 1
2011 1
2012 1
2014 2
2016 7
2017 3
2018 3
2019 2
2020 2
2022 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Garon EB, et al. Among authors: lewanski cr. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2. Lancet. 2014. PMID: 24933332 Clinical Trial.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Fehrenbacher L, et al. Among authors: lewanski c. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. Lancet. 2016. PMID: 26970723 Clinical Trial.
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.
Kunkler IH, Russell NS, Anderson N, Sainsbury R, Dixon JM, Cameron D, Loncaster J, Hatton M, Westenberg H, Clarke J, McCarty H, Evans R, Geropantas K, Wolstenholme V, Alhasso A, Woodings P, Barraclough L, Bayman N, Welch R, Muturi F, McEleney T, Burns J, Riddle K, Macdonald E, Dunlop J, Sergenson N, van Tienhoven G, Taylor KJ, Bartlett JMS, Piper T, Velikova G, Aird E, Chua B, Hurkmans C, Venables K, Williams LJ, Thomas JS, Hanby AM, Maclennan M, Cleator S, Verghese ET, Li Y, Wang S, Canney P; SUPREMO Trial Investigators; Sunil. Kunkler IH, et al. N Engl J Med. 2025 Nov 6;393(18):1771-1783. doi: 10.1056/NEJMoa2412225. N Engl J Med. 2025. PMID: 41191939 Free PMC article. Clinical Trial.
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. Senan S, et al. Among authors: lewanski c. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811519 Clinical Trial.
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Pinato DJ, et al. Among authors: lewanski c. JAMA Oncol. 2019 Dec 1;5(12):1774-1778. doi: 10.1001/jamaoncol.2019.2785. JAMA Oncol. 2019. PMID: 31513236 Free PMC article.
Radiotherapy and cellular signalling.
Lewanski CR, Gullick WJ. Lewanski CR, et al. Lancet Oncol. 2001 Jun;2(6):366-70. doi: 10.1016/S1470-2045(00)00391-0. Lancet Oncol. 2001. PMID: 11905753 Review.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Popat S, Januszewski A, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Morris C, Ngai Y, Hughes L, Hackshaw A, Wilson W. Popat S, et al. Among authors: lewanski c. Br J Cancer. 2025 Feb;132(3):245-252. doi: 10.1038/s41416-024-02901-6. Epub 2024 Dec 5. Br J Cancer. 2025. PMID: 39639088 Free PMC article. Clinical Trial.
The risks of treating keloids with radiotherapy.
Botwood N, Lewanski C, Lowdell C. Botwood N, et al. Among authors: lewanski c. Br J Radiol. 1999 Dec;72(864):1222-4. doi: 10.1259/bjr.72.864.10703484. Br J Radiol. 1999. PMID: 10703484 Review.
38 results